Moving Faster, With Confidence: An Interview With Ulrike Bauer, Chief Business Officer At Ypsomed

Pressure to shorten development timelines keeps rising, yet speed alone can simply move risk and bottlenecks further downstream.

In this interview, Ulrike Bauer, Chief Business Officer at Ypsomed, makes the case that acceleration depends on pairing platform flexibility with readiness: the data, documentation, manufacturing and supply needed to keep a program moving without avoidable iteration. She considers how that balance differs for clinical-stage programs, including earlier device introduction in Phase 2, and for generic and biosimilar pathways. She also looks past approval to the constraints that can surface at commercial scale, from local manufacturing in China and the US to the interfaces between device, container, fill-finish and assembly.

Watch the interview to hear her perspective on keeping drug delivery off the critical path.